Mason Marks

962 total citations · 1 hit paper
21 papers, 519 citations indexed

About

Mason Marks is a scholar working on Clinical Psychology, Organic Chemistry and Information Systems and Management. According to data from OpenAlex, Mason Marks has authored 21 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Clinical Psychology, 9 papers in Organic Chemistry and 4 papers in Information Systems and Management. Recurrent topics in Mason Marks's work include Psychedelics and Drug Studies (12 papers), Chemical synthesis and alkaloids (9 papers) and Diverse academic research themes (4 papers). Mason Marks is often cited by papers focused on Psychedelics and Drug Studies (12 papers), Chemical synthesis and alkaloids (9 papers) and Diverse academic research themes (4 papers). Mason Marks collaborates with scholars based in United States, Netherlands and Denmark. Mason Marks's co-authors include Claudia E. Haupt, I. Glenn Cohen, Carmel Shachar, Rebecca Weintraub Brendel, Nina Hallowell, Mackenzie Graham, Phoebe Friesen, Rachel Douglas‐Jones, Huw Davies and Carissa Véliz and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Medicine.

In The Last Decade

Mason Marks

21 papers receiving 505 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AI-Generated Medical Advice—GPT and Beyond

2023 212 citations Claudia E. Haupt, Mason Marks JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mason Marks United States	10	219	149	116	92	79	21	519
I. Féki Tunisia	8	43 0.2×	60 0.4×	144 1.2×	20 0.2×	93 1.2×	67	422
Samantha Winter United States	8	109 0.5×	89 0.6×	183 1.6×		38 0.5×	9	466
Yon Hee Seo South Korea	8	125 0.6×	30 0.2×	91 0.8×		31 0.4×	16	323
David T. Marc United States	9	105 0.5×	6 0.0×	79 0.7×	4 0.0×	38 0.5×	26	656
Taylor C. Ryan United States	6	51 0.2×	119 0.8×	97 0.8×	2 0.0×	24 0.3×	10	404
Thomas Krendl Gilbert United States	8	75 0.3×	45 0.3×	81 0.7×		25 0.3×	17	282
Vikram Singh Rawat India	12	17 0.1×	58 0.4×	21 0.2×	5 0.1×	21 0.3×	34	531
Yan Luo United States	10	8 0.0×	37 0.2×	29 0.3×	34 0.4×	4 0.1×	50	346
Stefano Forti Italy	14	12 0.1×	64 0.4×	81 0.7×	3 0.0×	26 0.3×	36	624

Countries citing papers authored by Mason Marks

Since Specialization

Citations

This map shows the geographic impact of Mason Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mason Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mason Marks more than expected).

Fields of papers citing papers by Mason Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mason Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mason Marks. The network helps show where Mason Marks may publish in the future.

Co-authorship network of co-authors of Mason Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Mason Marks. A scholar is included among the top collaborators of Mason Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mason Marks. Mason Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Cohen, I. Glenn & Mason Marks. (2025). Psychedelic Medicine Exceptionalism. The American Journal of Bioethics. 25(1). 6–15. 10 indexed citations

2.

Marks, Mason, Rebecca Weintraub Brendel, Carmel Shachar, & I. Glenn Cohen. (2024). Essentials of Informed Consent to Psychedelic Medicine. JAMA Psychiatry. 81(6). 611–611. 19 indexed citations

3.

Marks, Mason & Carmel Shachar. (2023). Drug scheduling limits access to essential medicines and should be reformed. Nature Medicine. 29(2). 294–297. 7 indexed citations

4.

Marks, Mason, Brent M. Kious, Carmel Shachar, & I. Glenn Cohen. (2023). Introducing psychedelics to end-of-life mental healthcare. Nature Mental Health. 1(12). 920–922. 4 indexed citations

5.

Marks, Mason & Claudia E. Haupt. (2023). AI Chatbots, Health Privacy, and Challenges to HIPAA Compliance. JAMA. 330(4). 309–309. 83 indexed citations

6.

Marks, Mason & I. Glenn Cohen. (2023). How Should the FDA Evaluate Psychedelic Medicine?. New England Journal of Medicine. 389(19). 1733–1735. 8 indexed citations

7.

Haupt, Claudia E. & Mason Marks. (2023). AI-Generated Medical Advice—GPT and Beyond. JAMA. 329(16). 1349–1349. 212 indexed citations breakdown →

8.

Marks, Mason. (2023). State-Regulated Psychedelics on a Collision Course With FDA. JAMA. 330(24). 2337–2337. 5 indexed citations

9.

Marks, Mason. (2022). The varieties of psychedelic law. Neuropharmacology. 226. 109399–109399. 33 indexed citations

10.

Marks, Mason. (2022). The Varieties of Psychedelic Law. SSRN Electronic Journal. 1 indexed citations

11.

Marks, Mason & I. Glenn Cohen. (2021). Psychedelic therapy: a roadmap for wider acceptance and utilization. Nature Medicine. 27(10). 1669–1671. 42 indexed citations

12.

Marks, Mason. (2021). Automating FDA Regulation. SSRN Electronic Journal. 1 indexed citations

13.

Marks, Mason & I. Glenn Cohen. (2021). Patents on Psychedelics: The Next Legal Battlefront of Drug Development. SSRN Electronic Journal. 9 indexed citations

14.

Friesen, Phoebe, Rachel Douglas‐Jones, Mason Marks, et al.. (2021). Governing AI‐Driven Health Research: Are IRBs Up to the Task?. PubMed. 43(2). 35–42. 26 indexed citations

15.

Marks, Mason. (2020). Emergent Medical Data: Health Information Inferred by Artificial Intelligence. eYLS (Yale Law School). 11(4). 995. 7 indexed citations

16.

Marks, Mason. (2020). Biosupremacy: Big Data, Antitrust, and Monopolistic Power Over Human Behavior. SSRN Electronic Journal. 2 indexed citations

17.

Marks, Mason. (2020). Controlled Substance Regulation for the COVID-19 Mental Health Crisis. SSRN Electronic Journal. 5 indexed citations

18.

Marks, Mason. (2019). Artificial Intelligence Based Suicide Prediction. eYLS (Yale Law School). 25 indexed citations

19.

Marks, Mason. (2019). Robots in Space: Sharing Our World with Autonomous Delivery Vehicles. SSRN Electronic Journal. 12 indexed citations

20.

Marks, Mason. (2017). Psychedelic Medicine for Mental Illness and Substance Use Disorders: Overcoming Social and Legal Obstacles. SSRN Electronic Journal. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact